Hi {{first name | there}},

Heart disease has shaped my family.

My dad survived a massive heart attack and eventually needed a heart transplant. My grandfather spent the last six years of his life bed-bound after a stroke.

Then my own LDL came back at 192 mg/dL.

A PCSK9 inhibitor changed my trajectory. I take Repatha every two weeks, and my LDL dropped to roughly 40 mg/dL. The injection is manageable. Most people would still rather take a pill, and plenty will never start an injectable for a risk they cannot feel.

On Thursday, the FDA approved Lipfendra, or enlicitide, the first oral PCSK9 inhibitor in the United States. In Phase 3 trials, it lowered LDL by roughly 56–59% versus placebo and ApoB by about 50%.

That is injectable-class LDL lowering in a once-daily tablet.

While not as sexy as GLP-1 inhibitors, I strongly believe this and other effective, well-tolerated lipid-lowering and atherosclerosis-preventing interventions will have such a large impact on healthspan and lifespan that they will transform the field entirely.

So how did we discover such an incredible mechanism of intervention, and why am I so convinced of its safety and efficacy for longevity?

In 2003, researchers led by Nabil Seidah described a liver-expressed protein they called NARC-1, soon renamed PCSK9. Within months, a French team found gain-of-function variants in PCSK9 in families with severe inherited high cholesterol.

Too much PCSK9 activity meant much higher LDL.

Then the experiment ran in the opposite direction.

Researchers then found people with variants that disabled one copy of PCSK9. In a 2006 New England Journal of Medicine analysis:

If you’re paying attention to drug intervention studies, you might notice that 28% isn’t as big of a difference than what statins and some other medications can do for lipid-lowering. And yet the outcome we care about - coronary heart disease - is lowered far more than seen in drug trials.

The takeaway? A modest LDL reduction maintained from birth can produce a much larger clinical benefit than the same numerical reduction started after decades of exposure.

Your liver clears LDL particles using LDL receptors on hepatocytes.

An LDL receptor grabs an LDL particle, brings it into the cell, releases the cargo, then normally returns to the cell surface. The receptor is reusable.

PCSK9 changes the route. When PCSK9 binds the receptor, the complex is directed toward degradation instead of recycling.

Fewer receptors survive. The liver clears less LDL.

Think of it as a disposal tag: PCSK9 marks the LDL receptor for the trash. Block PCSK9, and the liver gets to reuse more receptors which grab more LDL particles.

Because PCSK9 mainly works as a binding and trafficking protein with a broad protein-protein interface, we need antibody-type drugs, which typically come as injections rather than small pills. But of course, injections have lower adherence than pills.

The last 23 years have been a series of answers to that engineering problem.

Mechanism is only part of the choice. The drug still has to lower ApoB enough, have evidence that matches the person's risk, and fit real life.

The first successful drugs were the monoclonal antibodies evolocumab, or Repatha, and alirocumab, or Praluent.

These antibodies circulate in the blood, bind PCSK9, and prevent it from attaching to the LDL receptor.

The mechanism is direct and reversible: stop giving the antibody, and the effect gradually fades.

Both drugs were approved in 2015. Then came the outcome trials. In FOURIER, evolocumab lowered LDL by 59% and cut the primary cardiovascular endpoint from 11.3% to 9.8%. In ODYSSEY OUTCOMES, alirocumab cut its primary endpoint from 11.1% to 9.5%.

Repatha is part of my own care. It works, but it is still an injector pen that lives in the refrigerator, which doesn’t fit a lot of people’s routines.

Inclisiran works one step upstream.

Instead of catching PCSK9 after the liver makes it, inclisiran enters hepatocytes and helps a cellular RNA-silencing system destroy PCSK9 messenger RNA. No message, less protein.

This is small-interfering RNA, or siRNA. It is not gene editing. It does not change the DNA sequence, and it is not an epigenetic therapy.

The molecule is attached to GalNAc, a sugar structure that helps it enter liver cells through a hepatocyte receptor. After doses on day 1 and day 90, it is given every six months by a clinician.

In the ORION-10 and ORION-11 trials, inclisiran lowered LDL by about 50% versus placebo over 18 months. The FDA approved it in December 2021.

The appeal is obvious: two documented clinic doses a year can solve a very different adherence problem from a daily pill or a self-injection every two weeks.

Its limitation is equally clear. Inclisiran does not yet have the same completed cardiovascular-outcomes evidence as evolocumab and alirocumab. LDL lowering strongly predicts benefit here, but product- and modality-specific outcomes still matter.

Lipfendra acts at the protein layer again, like the antibodies. The technical trick is how it gets there.

Enlicitide is not a conventional tiny small molecule. It is a macrocyclic peptide, an engineered ring-shaped molecule large enough to grip PCSK9's broad binding surface but compact and stable enough to formulate as a tablet.

The tablet also contains sodium caprate, which facilitates intestinal absorption. The FDA-approved label reports oral bioavailability of only about 1%.

Only about 1% reaches circulation. That is enough because enlicitide binds PCSK9 so tightly that the absorbed fraction can reduce free PCSK9 by more than 90% near peak concentration.

The pivotal numbers:

The AddOn study was short, and its bempedoic-acid result was lower than the effect generally quoted from the broader literature. It proves comparative lipid potency in that trial, not superiority for cardiovascular outcomes, cost, or every patient.

Lipfendra is taken once daily in the morning on an empty stomach with the only exceptions being water, black coffee, or plain tea. Then you wait at least 30 minutes before other food or drinks.

Taking the pill after a meal cut drug exposure by about half.

Some people will happily do that to avoid needles. Others will find a shot every two or four weeks easier than coordinating breakfast every morning.

Lipfendra is approved to reduce LDL.

It has not yet been shown that this specific drug prevents heart attacks, strokes, or cardiovascular death.

CORALreef Outcomes is testing enlicitide in about 14,550 high-risk participants. The registry estimates primary completion in November 2029.

The LDL lowering is proven. Lipfendra-specific cardiac event reduction is not yet.

VERVE-102 packages an adenine base editor and a guide RNA inside a liver-targeting lipid nanoparticle. The guide directs the editor to a splice site at the beginning of the first intron of PCSK9. A single DNA-letter change disrupts normal processing of the gene and prevents normal PCSK9 production in hepatocytes.

This is not “fixing the cholesterol gene.” Most people with high LDL do not have a pathogenic gain-of-function mutation in PCSK9. The therapy is trying to create a protective loss-of-function state in the liver.

In an ongoing Phase 1 study published in May, 35 participants with HeFH or premature coronary disease received one infusion across six dose groups.

At the highest dose:

The reductions appeared durable, and 15 participants had at least one year of follow-up. Mild-to-moderate infusion reactions and temporary ALT elevations occurred. No dose-limiting toxicity was reported in the interim dataset.

A separate program, YOLT-101, reported 52.3% LDL lowering at 24 weeks in the highest-dose cohort, although this was only three people large.

This is exciting, but permanent editing changes the consent calculus. A rare delayed off-target, immune, hepatic, or delivery-related effect cannot be managed by simply stopping the pill.

Epigenetic editing is the proposed middle path.

Instead of changing the DNA sequence, an epigenetic editor can bring machinery to a gene and install chemical or chromatin marks that reduce transcription.

A 2025 Nature Medicine study used this approach against human PCSK9:

Scribe's STX-1150 has now received Australian regulatory clearance for a first-in-human study. The company says enrollment is underway in adults with elevated LDL and increased cardiovascular risk.

Its current LDL numbers are still preclinical. Scribe reports up to 68% LDL lowering in nonhuman primates and more than 50% lowering for over 22 months at its lowest prototype dose.

And “does not alter DNA sequence” is not the same as “easy to reverse.” The whole point is to make the silencing last for years. In the mouse experiment, reversal required a second targeted epigenetic activator. A person cannot simply stop taking it the next morning.

Epigenetic editing preserves the DNA you’re born with, but the silencing is intentionally durable. Whether it can be safely and practically reversed in humans is unproven.

On a lab report, these approaches can look surprisingly similar. What changes is the burden, the evidence, and what happens if you want out.

These are the two questions I am already getting.

Not by default. In CORALreef Lipids, 97% of participants were taking a statin. The trial mainly tested enlicitide as an add-on to existing therapy, not as proof that statins had become obsolete.

Statins remain inexpensive and have decades of cardiovascular-outcomes evidence. Lipfendra may be especially useful when someone cannot tolerate an adequate statin regimen, still needs a large LDL and ApoB reduction despite other treatment, or wants PCSK9 potency without an injection. But Lipfendra's own outcomes trial is still underway.

Usually no. Repatha and Praluent already bind circulating PCSK9. Enlicitide blocks the same extracellular PCSK9-LDL-receptor interaction. The pivotal Lipfendra trial explicitly excluded people taking other PCSK9 inhibitors, so we do not have evidence that stacking them adds meaningful LDL lowering, improves outcomes, or is the best use of two drugs aimed at the same step.

Inclisiran works one layer upstream by reducing PCSK9 production. Combining it with enlicitide is also not an established routine strategy.

For most people, this is a route choice, not a stack: daily fasting pill, self-injected antibody, or twice-yearly clinician-administered siRNA. If an injectable is working and LDL and ApoB are already at goal, the pill is not automatically an upgrade.

For me, with LDL around 40 mg/dL on Repatha, there is no obvious reason to add enlicitide. The relevant question would be whether to switch. Right now, I would not abandon a working drug with direct outcomes evidence just because the new option is oral. Fasting instructions, coverage, and the pending outcomes trial all matter.

If more lowering is still needed, I would first check whether the current regimen is being taken and administered correctly, then consider a complementary pathway rather than automatically doubling up on PCSK9 therapy.

Ezetimibe remains generic and easy. Bempedoic acid has direct outcome evidence in statin-intolerant patients. Evolocumab and alirocumab have PCSK9-specific event reduction. Inclisiran solves a supervised-adherence problem. Lipfendra solves needle aversion for some people but creates a daily food-timing requirement.

Gene and epigenetic therapy are not yet routine clinical choices.

The questions I would ask are:

I ask that last question more aggressively as the treatment becomes harder to undo.

PCSK9 is one tool inside a much larger prevention system. If you are trying to make sense of ApoB versus LDL-C, a high Lp(a), a CAC score of zero, whether CCTA adds anything, statin symptoms, lifestyle, or which medication comes next, I built a separate first-principles guide:

How to Prevent Atherosclerosis: A First-Principles Guide to Lipids and Plaque

Atherosclerosis keeps score over time. Lowering particle burden earlier changes the biology before disease becomes visible.

The short version: lower cumulative ApoB particle exposure, control the forces that injure the artery wall, use imaging only when it changes a decision, and verify that the plan actually worked.

PCSK9 may be the best model we have for the future of preventive medicine: human genetics found the target, and pharmacology learned to copy that biology at progressively earlier layers.

protein → RNA → oral protein blocker → DNA → epigenetic transcription.

I expect Lipfendra to matter - a lot. A potent oral option could broaden PCSK9 treatment far beyond the people willing to inject themselves or deal with specialty-drug logistics.

If its outcome trial is positive, coverage is reasonable, and people can follow the fasting routine, it could become a major prevention drug.

Hillary Lin, MD

For the broader treatment ladder, watch I Treat Cholesterol Differently Now.

Science of Skin Summit, September 17–20, Austin; MVMNT Longevity Summit, September 22–23, Coronado; Science of Skin Longevity Summit, February 19–21, 2027, Scottsdale.

Reader-supported partner links may earn a commission at no extra cost to you. See my current recommendations and discount codes.

For physician-guided biological age testing, see the testing page. Have a question or topic you want covered? Reply to this email.

Was this forwarded to you? Subscribe here.

Educational only, not individualized medical advice. I have no financial relationship with Merck, Amgen, Novartis, or the other drug developers discussed in this issue.